statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to...

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

NovoCure Limited (NASDAQ:NVCR - Get Free Report)'s share price gapped down prior to trading on Wednesday after Wells Fargo  Company lowered their price target on the stock from $49.00 to...

NovoCure (NASDAQ:NVCR) Shares Gap Down  Following Analyst Downgrade

Vanguard Group Inc. trimmed its stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 0.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional...

Vanguard Group Inc. Sells 27,193 Shares of NovoCure Limited (NASDAQ:NVCR)

This is a signal that NVCR's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

NovoCure (NVCR, $15.49) Stochastic Oscillator left the overbought zone on April 01, 2024

This is a Bullish indicator signaling NVCR's price could rise from here. Traders may explore going long the stock or buying call options...

NovoCure (NVCR, $15.49) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 1, 2024

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will...

Novocure to Report First Quarter 2024 Financial Results

NovoCure Limited (NASDAQ:NVCR - Free Report) - Research analysts at Leerink Partnrs boosted their FY2025 EPS estimates for NovoCure in a report released on Wednesday, March 27th. Leerink Partnrs...

Leerink Partnrs Weighs in on NovoCure Limited's FY2025 Earnings (NASDAQ:NVCR)

NovoCure Limited (NASDAQ:NVCR - Free Report) - Analysts at Wedbush reduced their Q4 2025 earnings estimates for shares of NovoCure in a research report issued to clients and investors on...

Q4 2025 EPS Estimates for NovoCure Limited (NASDAQ:NVCR) Cut by Analyst

NovoCure Limited (NASDAQ:NVCR - Free Report) - Leerink Partnrs boosted their FY2025 EPS estimates for shares of NovoCure in a research report issued on Wednesday, March 27th. Leerink Partnrs...

Leerink Partnrs Analysts Raise Earnings Estimates for NovoCure Limited (NASDAQ:NVCR)

NovoCure Limited (NASDAQ:NVCR - Free Report) - Research analysts at Wedbush decreased their Q4 2025 earnings estimates for shares of NovoCure in a research report issued on Wednesday, March 27th...

Research Analysts Offer Predictions for NovoCure Limited's Q4 2025 Earnings (NASDAQ:NVCR)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Volume	762,109.00
52-Wk High	$83.60
52-Wk Low	$10.87

NVCR NovoCure Ltd

About

Feed

News

Sentiment

Earnings

Fundamentals